Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMGN REGN VRTX NBIX ALNY EXEL IONS PTCT MDGL NKTR

| Held by: VTI IWM VXF XPH IWN VTWO VHT IWO IWC PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	1.53%	Shs Outstand	239.06M	Perf Week	0.88%
Market Cap	819.99M	Forward P/E	19.93	EPS next Y	0.17	Insider Trans	-2.80%	Shs Float	235.40M	Perf Month	6.19%
Enterprise Value	1.33B	PEG	-	EPS next Q	0.27	Inst Own	62.19%	Short Float	14.21%	Perf Quarter	13.20%
Income	-105.83M	P/S	2.70	EPS this Y	82.36%	Inst Trans	4.01%	Short Ratio	6.07	Perf Half Y	65.70%
Sales	303.80M	P/B	-	EPS next Y	448.47%	ROA	-31.21%	Short Interest	33.45M	Perf YTD	-7.30%
Book/sh	-2.20	P/C	8.87	EPS next 5Y	-	ROE	-	52W High	4.18 -17.84%	Perf Year	83.42%
Cash/sh	0.39	P/FCF	-	EPS past 3/5Y	69.04% 40.11%	ROIC	-	52W Low	0.69 395.31%	Perf 3Y	-38.86%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	61.80% 17.50%	Gross Margin	58.20%	Volatility	5.14% 6.01%	Perf 5Y	-88.51%
Dividend TTM	-	EV/Sales	4.37	EPS Y/Y TTM	13.61%	Oper. Margin	-9.67%	ATR (14)	0.21	Perf 10Y	-77.01%
Dividend Ex-Date	-	Quick Ratio	0.70	Sales Y/Y TTM	2.83%	Profit Margin	-34.84%	RSI (14)	50.38	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	1.00	EPS Q/Q	-3.04%	SMA20	3.33%	Beta	1.10	Target Price	6.47
Payout	-	Debt/Eq	-	Sales Q/Q	69.10%	SMA50	-4.34%	Rel Volume	0.87	Prev Close	3.40
Employees	304	LT Debt/Eq	-	Earnings	Nov 06 BMO	SMA200	44.66%	Avg Volume	5.52M	Price	3.43
IPO	Jun 26, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-104.34% 13.09%	Trades		Volume	4,780,155	Change	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Initiated	Piper Sandler	Overweight	$9
Dec-18-24	Initiated	Goldman	Neutral	$4
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$8
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform	$2.50
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11
May-05-21	Downgrade	Stifel	Buy → Hold	$37 → $20

Show Previous Ratings

Feb-11-26 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-26 06:00PM	Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 08:00AM	Esperion's Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes (GlobeNewswire)
Dec-09-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Nov-21-25 08:00AM	Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia (GlobeNewswire)
Nov-19-25 08:00AM	Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-18-25 07:00AM	Esperion Partner HLS Therapeutics Announces Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease (GlobeNewswire)
Nov-10-25 08:00AM	Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 (GlobeNewswire) +8.27%
Nov-07-25 11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks) +6.40%
Nov-06-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -14.97%
02:06PM	Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Nov-04-25 08:00AM	Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer (GlobeNewswire)
Nov-03-25 08:00AM	Esperion to Participate in Jefferies Global Healthcare Conference - London (GlobeNewswire)
Oct-28-25 08:00AM	Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. (GlobeNewswire)
Oct-27-25 08:00AM	Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire) +7.01%
Oct-23-25 08:00AM	Esperion to Report Third Quarter 2025 Financial Results on November 6 (GlobeNewswire)
Oct-17-25 11:52AM	ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up (Zacks)
Oct-16-25 08:00AM	Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis (GlobeNewswire) +5.16%
Oct-10-25 01:01AM	ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play (MoneyShow)
Oct-09-25 08:57AM	ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering (Zacks)
Oct-07-25 09:29PM	Esperion Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -16.83%
04:01PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks) -5.45%
Oct-03-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 19, 2040 (GlobeNewswire) +13.79%
Sep-24-25 06:40AM	Oritain expands traceability offer to leather (Just Style)
Sep-19-25 08:00AM	Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia (GlobeNewswire)
08:00AM	Loading…
Aug-29-25 08:00AM	Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias (GlobeNewswire)
Aug-26-25 08:00AM	Esperion to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-22-25 03:11PM	Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock? (Zacks)
Aug-14-25 06:31AM	HLS Therapeutics Announces Q2 2025 Financial Results (PR Newswire) +6.70%
Aug-07-25 05:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.73%
Aug-06-25 11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks) +18.52%
Aug-05-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.72%
06:14AM	Esperion Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-29-25 10:00AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) -7.55%
09:34AM	Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors (Insider Monkey)
Jul-22-25 08:00AM	Esperion to Report Second Quarter 2025 Financial Results on August 5 (GlobeNewswire) +6.09%
Jul-17-25 07:00AM	Whats the Status on Digital Product Passport Implementation? (Sourcing Journal) +10.71%
Jul-08-25 08:00AM	Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +5.41%
Jul-01-25 08:06AM	Esperion Appoints Craig Thompson to Board of Directors (GlobeNewswire)
Jun-05-25 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? (Zacks)
Jun-02-25 08:00AM	Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +8.10%
May-20-25 08:00AM	Esperion to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.19%
May-12-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire)
May-09-25 09:55AM	HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines (Pharmaceutical Technology) -10.60%
08:00AM	Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:32AM	HLS Therapeutics Announces Q1 2025 Financial Results (PR Newswire)
06:30AM	HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada (PR Newswire)
06:30AM	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada (GlobeNewswire)
May-07-25 12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks) -10.72%
03:05AM	Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
May-06-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.10%
06:10AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.80%
Apr-25-25 08:00AM	Esperion to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -7.15%
08:00AM	Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 (GlobeNewswire)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:00AM	Esperion to Report First Quarter 2025 Financial Results on May 6 (GlobeNewswire)
Apr-22-25 09:35AM	Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +9.12%
Apr-21-25 05:32PM	Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -10.32%
Apr-10-25 08:00AM	Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 (GlobeNewswire) -8.57%
Apr-03-25 11:30AM	Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? (Zacks) -7.19%
Apr-01-25 08:00AM	Esperion Appoints Robert E. Hoffman to Board of Directors (GlobeNewswire)
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-24-25 08:00AM	Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 09:26AM	ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia (Zacks)
Mar-20-25 08:00AM	Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia (GlobeNewswire)
Mar-04-25 11:52PM	Q4 2024 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +12.03% -6.78%
07:10AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:17AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Esperion Partners with CSL Seqirus to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia (GlobeNewswire) -7.06%
Mar-01-25 07:24AM	Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now? (Insider Monkey)
Feb-25-25 10:00AM	Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-18-25 08:00AM	Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 (GlobeNewswire)
Feb-13-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-25 08:00AM	Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. (GlobeNewswire)
Jan-02-25 08:00AM	Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 07:00AM	Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions (GlobeNewswire) -12.20%
Dec-13-24 06:00AM	Esperion Announces $210 Million Convertible Debt Financing (GlobeNewswire) -11.76%
Dec-12-24 08:00AM	Esperion Partners with Neopharm to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Israel (GlobeNewswire) -5.20%
Dec-02-24 08:00AM	Esperion Announces New Drug Submissions in Canada for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk (GlobeNewswire) +10.71%
Nov-26-24 08:00AM	Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia (GlobeNewswire)
Nov-21-24 08:00AM	Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 10:30AM	Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-08-24 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.06% +10.53%
02:08AM	Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Nov-07-24 07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:08AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Looker Benjamin	General Counsel	Jan 20 '26	Sale	2.88	1,689	4,868	384,216	Jan 21 05:17 PM
Looker Benjamin	Officer	Jan 20 '26	Proposed Sale	2.88	1,689	4,867		Jan 20 03:14 PM
Koenig Sheldon L.	President and CEO	Dec 17 '25	Sale	3.67	48,244	177,200	1,470,587	Dec 18 04:10 PM
Halladay Benjamin	Chief Financial Officer	Dec 17 '25	Sale	3.67	7,337	26,905	467,525	Dec 18 04:09 PM
Looker Benjamin	General Counsel	Dec 17 '25	Sale	3.67	6,517	23,898	385,905	Dec 18 04:09 PM
Koenig Sheldon L.	Officer	Dec 17 '25	Proposed Sale	3.67	48,244	177,200		Dec 17 03:52 PM
Looker Benjamin	Officer	Dec 17 '25	Proposed Sale	3.67	6,517	23,897		Dec 17 03:26 PM
Halladay Benjamin	Officer	Dec 17 '25	Proposed Sale	3.67	7,337	26,906		Dec 17 03:18 PM
Looker Benjamin	Officer	Oct 17 '25	Proposed Sale	2.62	1,248	3,275		Oct 17 03:13 PM
Looker Benjamin	General Counsel	Sep 17 '25	Sale	2.80	6,267	17,573	393,670	Sep 18 04:06 PM
Koenig Sheldon L.	President and CEO	Sep 17 '25	Sale	2.79	28,427	79,254	1,518,831	Sep 18 04:06 PM
Halladay Benjamin	Chief Financial Officer	Sep 17 '25	Sale	2.81	7,046	19,785	474,862	Sep 18 04:06 PM
Koenig Sheldon L.	Officer	Sep 17 '25	Proposed Sale	2.79	28,427	79,240		Sep 17 03:37 PM
Halladay Benjamin	Officer	Sep 17 '25	Proposed Sale	2.81	7,046	19,789		Sep 17 03:30 PM
Looker Benjamin	Officer	Sep 17 '25	Proposed Sale	2.80	6,267	17,576		Sep 17 03:25 PM
Looker Benjamin	General Counsel	Jul 17 '25	Sale	1.13	1,304	1,470	399,937	Jul 18 04:07 PM
Halladay Benjamin	Chief Financial Officer	Jul 17 '25	Sale	1.11	11	12	474,462	Jul 18 04:05 PM
Looker Benjamin	Officer	Jul 17 '25	Proposed Sale	1.13	1,304	1,469		Jul 17 05:09 PM
Halladay Benjamin	Officer	Jul 17 '25	Proposed Sale	1.12	11	12		Jul 17 03:39 PM
Looker Benjamin	General Counsel	Jun 17 '25	Sale	1.15	6,422	7,398	401,241	Jun 18 06:45 PM
Koenig Sheldon L.	President and CEO	Jun 17 '25	Sale	1.11	30,474	33,796	1,541,488	Jun 18 06:44 PM
Halladay Benjamin	Chief Financial Officer	Jun 17 '25	Sale	1.15	7,229	8,328	474,473	Jun 18 06:44 PM
Koenig Sheldon L.	Officer	Jun 17 '25	Proposed Sale	1.11	30,474	33,793		Jun 17 04:11 PM
Halladay Benjamin	Officer	Jun 17 '25	Proposed Sale	1.15	7,229	8,329		Jun 17 03:34 PM
Looker Benjamin	Officer	Jun 17 '25	Proposed Sale	1.15	6,422	7,398		Jun 17 03:16 PM
Warren Eric	Chief Commercial Officer	Apr 17 '25	Sale	0.98	108	106	370,218	Apr 21 04:04 PM
Halladay Benjamin	Chief Financial Officer	Apr 17 '25	Sale	0.96	8	8	481,702	Apr 21 04:03 PM
Halladay Benjamin	Officer	Apr 17 '25	Proposed Sale	0.96	8	8		Apr 17 03:14 PM
Warren Eric	Officer	Apr 17 '25	Proposed Sale	0.98	108	106		Apr 17 03:08 PM
Halladay Benjamin	Chief Financial Officer	Mar 18 '25	Sale	1.48	3,535	5,242	481,710	Mar 19 04:03 PM
Warren Eric	Chief Commercial Officer	Mar 18 '25	Sale	1.49	2,433	3,618	370,326	Mar 19 04:02 PM
Koenig Sheldon L.	President and CEO	Mar 18 '25	Sale	1.50	13,047	19,623	1,571,962	Mar 19 04:02 PM
Warren Eric	Officer	Mar 18 '25	Proposed Sale	1.49	2,433	3,618		Mar 18 03:23 PM
Halladay Benjamin	Officer	Mar 18 '25	Proposed Sale	1.48	3,535	5,243		Mar 18 03:20 PM
Koenig Sheldon L.	Officer	Mar 18 '25	Proposed Sale	1.50	13,047	19,619		Mar 18 03:11 PM
Warren Eric	Chief Commercial Officer	Feb 19 '25	Sale	1.87	239	446	159,759	Feb 20 04:50 PM
Halladay Benjamin	Chief Financial Officer	Feb 19 '25	Sale	1.86	11	20	240,671	Feb 20 04:50 PM
Warren Eric	Officer	Feb 19 '25	Proposed Sale	1.87	239	446		Feb 19 03:34 PM
Halladay Benjamin	Officer	Feb 19 '25	Proposed Sale	1.86	11	20		Feb 19 03:26 PM

Open in Screener

EXAS

Exact Sciences Corp

Feb 13 • 04:00PM ET

103.24

+0.01 0.01 %

Healthcare • Diagnostics & Research • USA • NASD

EXAS Exact Sciences Corp daily Stock Chart

Peers: ILMN GH NTRA TXG DGX FLGT BIO QDEL MYGN CSTM

| Held by: VTI VB VBK VXF XBI FBT IWR VHT SCHM IWD

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	1.93%	Shs Outstand	190.80M	Perf Week	0.06%
Market Cap	19.70B	Forward P/E	84.19	EPS next Y	1.23	Insider Trans	-0.70%	Shs Float	187.13M	Perf Month	0.96%
Enterprise Value	21.27B	PEG	-	EPS next Q	-0.18	Inst Own	88.11%	Short Float	3.55%	Perf Quarter	51.00%
Income	-207.95M	P/S	6.07	EPS this Y	126.94%	Inst Trans	-4.73%	Short Ratio	1.27	Perf Half Y	129.47%
Sales	3.25B	P/B	8.20	EPS next Y	313.76%	ROA	-3.39%	Short Interest	6.65M	Perf YTD	1.65%
Book/sh	12.58	P/C	20.42	EPS next 5Y	-	ROE	-8.66%	52W High	103.54 -0.29%	Perf Year	104.07%
Cash/sh	5.06	P/FCF	55.21	EPS past 3/5Y	32.20% 27.36%	ROIC	-4.25%	52W Low	38.81 166.00%	Perf 3Y	57.84%
Dividend Est.	-	EV/EBITDA	322.75	Sales past 3/5Y	15.92% 16.84%	Gross Margin	69.69%	Volatility	0.25% 0.33%	Perf 5Y	-33.40%
Dividend TTM	-	EV/Sales	6.55	EPS Y/Y TTM	-353.69%	Oper. Margin	-4.79%	ATR (14)	0.41	Perf 10Y	1658.77%
Dividend Ex-Date	-	Quick Ratio	2.17	Sales Y/Y TTM	17.69%	Profit Margin	-6.40%	RSI (14)	73.44	Recom	2.81
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	90.29%	SMA20	0.56%	Beta	1.41	Target Price	104.00
Payout	-	Debt/Eq	1.06	Sales Q/Q	23.12%	SMA50	1.16%	Rel Volume	0.41	Prev Close	103.23
Employees	7200	LT Debt/Eq	1.04	Earnings	Feb 13 AMC	SMA200	50.91%	Avg Volume	5.22M	Price	103.24
IPO	Jan 31, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	-317.05% 2.03%	Trades		Volume	2,120,491	Change	0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-20-26	Downgrade	Mizuho	Outperform → Neutral	$105
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$105
Apr-10-25	Initiated	Mizuho	Outperform	$60
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$52
Jan-23-25	Initiated	Barclays	Overweight	$70
Aug-28-24	Initiated	Wells Fargo	Overweight	$75
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$70
Jun-03-24	Resumed	Jefferies	Buy	$75
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35

Show Previous Ratings

Feb-13-26 05:15PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Exact Sciences: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-12-26 01:04PM	Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next? (24/7 Wall St.)
Feb-09-26 11:01AM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
11:04PM	Loading…
Feb-08-26 11:04PM	Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Feb-06-26 05:41PM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
Feb-03-26 02:32PM	Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests (Business Wire)
09:03AM	Oncotype DX Breast Recurrence Score Test Surpasses 2 Million Patients Worldwide (Business Wire)
08:30AM	Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 (Insider Monkey)
Feb-02-26 12:05PM	The Best Dividend King to Buy With $150 (Motley Fool)
Jan-28-26 06:46AM	Medtech M&A took off in the second half of 2025: report (MedTech Dive)
Jan-27-26 11:40AM	EXEL vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
07:46AM	Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement (Insider Monkey)
Jan-26-26 06:40AM	3 Reasons to Buy This Dividend King After Its Steep Sell-Off (Motley Fool)
04:02PM	Loading…
Jan-22-26 04:02PM	Abbott Falls Most in Nearly 24 Years on Formula Pricing Stumble (Bloomberg)
04:01PM	Abbott Laboratories (ABT) Q4 2025 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
09:48AM	Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints (Benzinga)
08:53AM	Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms (Investor's Business Daily)
Jan-20-26 08:47AM	Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott (Insider Monkey)
07:55AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Chevron, Dominos Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More (24/7 Wall St.)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 07:51AM	Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold? (Zacks)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
12:48PM	Halper Sadeh LLC Encourages FRGE, EXAS, CIVI, KVUE Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
12:21PM	CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois (Zacks)
Jan-07-26 12:31PM	Select Medical Expands Rehab Footprint Through Vibra Healthcare JV (Zacks)
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:49AM	Loading…
11:49AM	JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus (Zacks)
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
11:00AM	Halper Sadeh LLC Encourages EXAS, SOAR, BTBD Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-04-26 11:32PM	1 High-Flying Stock on Our Watchlist and 2 We Question (StockStory)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
07:32AM	How Tempus AI Is Building Scale While Near-Term Risks Persist (Zacks)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-11-25 05:30PM	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS (Business Wire)
Dec-10-25 11:35PM	1 Healthcare Stock for Long-Term Investors and 2 We Avoid (StockStory)
Dec-08-25 01:35AM	Freenome inks deals to list stock and raise $330M (MedTech Dive)
Dec-05-25 09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
Dec-03-25 11:30AM	Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? (Zacks)
Dec-02-25 04:54AM	Here's Why Grail Soared, Again, in November (Motley Fool)
Dec-01-25 12:33PM	Cathie Wood dumps $8.46 million in software giant (TheStreet)
Nov-30-25 02:05AM	This Top Dividend King Just Became an Even Better Buy (Motley Fool)
Nov-28-25 12:41PM	Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 09:36AM	Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More (24/7 Wall St.)
01:33AM	Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-24-25 04:35PM	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium (Business Wire)
09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-23-25 10:30PM	Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks (StockStory)
Nov-21-25 09:10AM	Here Are Fridays Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More (24/7 Wall St.)
07:32AM	Health Care Roundup: Market Talk (The Wall Street Journal)
06:30AM	Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase (The Daily Upside)
04:50AM	Abbott to acquire all outstanding shares in Exact Sciences (Medical Device Network)
03:35AM	Stock Market Today: Dow Futures Inch Up; Bitcoin Slides; VIX Jumps (The Wall Street Journal)
Nov-20-25 07:50PM	Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire) +16.81%
07:43PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
06:29PM	Why the Stock Price of This Cancer Screening Company Soared 17% Thursday (Investopedia)
05:06PM	Health Care Roundup: Market Talk (The Wall Street Journal)
05:05PM	Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
04:44PM	Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More (Motley Fool)
04:23PM	These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More (Barrons.com)
04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
04:14PM	Exact Sciences Catapults On $23 Billion Abbott Labs Buyout (Investor's Business Daily)
03:31PM	Why Exact Sciences Rallied Over 50% This Week (Motley Fool)
03:08PM	Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences (Chicago Tribune)
03:03PM	Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? (Barchart)
03:01PM	Why Exact Sciences Stock Surged Today (Motley Fool)
02:47PM	These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More (Barrons.com)
01:36PM	Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
01:02PM	Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More (Investopedia)
12:01PM	Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know (Milwaukee Journal Sentinel)
11:51AM	Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion (Barrons.com)
11:32AM	What to know about Exact Sciences. The Madison company was sold to Abbot for $23 billion. (Milwaukee Journal Sentinel)
10:21AM	Exact Sciences Soars As Abbott Unveils $21 Billion Buyout (GuruFocus.com)
09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
09:31AM	Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences (Financial Times)
09:26AM	Abbott to buy Exact Sciences for $21B, Verizon to cut 13K jobs (Yahoo Finance Video)
08:43AM	Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test (MarketWatch)
08:09AM	Exact Sciences stock jumps after Abbott confirms acquisition (Investing.com)
07:46AM	Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. (Barrons.com)
07:46AM	Abbott to Acquire Exact Sciences for $21 Billion (The Wall Street Journal)
07:30AM	Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments (PR Newswire)
06:27AM	Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports (Insider Monkey)
Nov-19-25 07:21PM	Why Exact Sciences Stock Blasted Nearly 24% Higher Today (Motley Fool) +23.68%
04:57PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
04:31PM	Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories Buyout (Investor's Business Daily)
04:27PM	Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories (Barrons.com)
02:36PM	Exact Sciences shares soar on report Abbott is nearing deal for the company (Investing.com)
11:19AM	Stock Market Today: Fed Minutes Weigh on U.S. Equities As Traders Await News (TheStreet)
06:22AM	Freenome and Roche partner on cancer screening technology for ex-US markets (Medical Device Network)
Nov-17-25 01:13PM	Molina Secures Deal From AHCA to Serve Florida's Medicaid Members (Zacks)
Nov-15-25 09:00AM	Alphabets Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too? (24/7 Wall St.)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORVILLE JACOB A	EVP, GM, Screening	Dec 23 '25	Option Exercise	0.00	73,080	0	69,511	Dec 30 04:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Dec 23 '25	Option Exercise	0.00	73,080	0	66,487	Dec 30 04:30 PM
Condella Sarah	EVP, Human Resources	Dec 23 '25	Option Exercise	0.00	47,208	0	118,059	Dec 30 04:30 PM
Herriott James	SVP, General Counsel & Sec	Dec 23 '25	Option Exercise	0.00	33,780	0	32,934	Dec 30 04:30 PM
Bloomer Aaron	EVP, Chief Financial Officer	Dec 23 '25	Option Exercise	0.00	63,099	0	59,571	Dec 30 04:30 PM
ORVILLE JACOB A	EVP, GM, Screening	Nov 19 '25	Sale	75.00	5,000	375,000	23,237	Nov 21 05:30 PM
Herriott James	SVP, General Counsel & Sec	Nov 19 '25	Sale	70.00	1,000	70,000	11,585	Nov 21 05:30 PM
ORVILLE JACOB A	Officer	Nov 19 '25	Proposed Sale	75.00	5,000	375,000		Nov 19 03:11 PM
Herriott James	Officer	Nov 19 '25	Proposed Sale	70.00	1,000	70,000		Nov 19 12:04 PM
Herriott James	SVP, General Counsel & Sec	Nov 04 '25	Sale	70.08	1,500	105,120	12,585	Nov 06 05:29 PM
Baranick Brian	EVP, GM, Precision Oncology	Nov 04 '25	Sale	70.08	2,858	200,289	22,368	Nov 06 05:29 PM
Baranick Brian	Officer	Nov 04 '25	Proposed Sale	70.08	2,858	200,289		Nov 04 10:25 AM
Herriott James	Officer	Nov 04 '25	Proposed Sale	70.08	1,500	105,120		Nov 04 10:22 AM
Zanotti Katherine S	Director	Oct 24 '25	Sale	65.00	12,000	780,000	60,759	Oct 27 08:35 PM
Zanotti Katherine S	Director	Oct 24 '25	Proposed Sale	65.00	12,000	780,000		Oct 24 11:08 AM
Herriott James	SVP, General Counsel & Sec	Oct 09 '25	Sale	60.00	1,500	90,000	14,085	Oct 10 05:27 PM
Doyle James Edward	Director	Oct 09 '25	Sale	60.00	2,000	120,000	57,962	Oct 10 05:25 PM
Herriott James	Officer	Oct 09 '25	Proposed Sale	60.00	1,500	90,000		Oct 09 11:23 AM
Doyle James Edward	Director	Oct 09 '25	Proposed Sale	60.00	2,000	120,000		Oct 09 11:18 AM
Doyle James Edward	Director	Aug 13 '25	Sale	42.02	1,485	62,400	59,962	Aug 14 04:30 PM
Doyle James Edward	Director	Aug 13 '25	Proposed Sale	42.02	1,485	62,400		Aug 13 10:09 AM
ORVILLE JACOB A	EVP, GM, Screening	Aug 05 '25	Option Exercise	0.00	5,350	0	30,752	Aug 07 05:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Aug 05 '25	Option Exercise	0.00	5,350	0	27,943	Aug 07 05:30 PM
Sebelius Kathleen	Former Director	Jul 16 '25	Proposed Sale	53.11	8,164	433,605		Jul 16 04:22 PM
Zanotti Katherine S	Director	Jun 13 '25	Sale	53.20	3,207	170,612	72,759	Jun 16 05:30 PM
Zanotti Katherine S	Director	Jun 13 '25	Proposed Sale	53.20	3,207	170,612		Jun 13 09:50 AM
Bloomer Aaron	EVP, Chief Financial Officer	Apr 15 '25	Option Exercise	0.00	24,460	0	19,340	Apr 17 04:30 PM
Conroy Kevin T	President and CEO	Mar 07 '25	Option Exercise	22.38	66,723	1,493,261	1,203,269	Mar 10 05:00 PM
Herriott James	SVP, General Counsel & Sec	Feb 28 '25	Option Exercise	0.00	4,265	0	16,339	Mar 04 04:48 PM
Conroy Kevin T	President and CEO	Feb 28 '25	Option Exercise	0.00	40,310	0	1,146,965	Mar 04 04:47 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 28 '25	Option Exercise	0.00	9,673	0	25,106	Mar 04 04:44 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 28 '25	Option Exercise	0.00	9,673	0	27,728	Mar 04 04:40 PM
Condella Sarah	EVP, Human Resources	Feb 28 '25	Option Exercise	0.00	7,738	0	84,399	Mar 04 04:37 PM
Condella Sarah	EVP, Human Resources	Feb 25 '25	Option Exercise	0.00	3,954	0	80,297	Feb 26 08:00 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 25 '25	Option Exercise	0.00	3,954	0	19,841	Feb 26 08:00 PM
Herriott James	SVP, General Counsel & Sec	Feb 25 '25	Option Exercise	0.00	1,647	0	13,738	Feb 26 08:00 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 25 '25	Option Exercise	0.00	3,954	0	22,136	Feb 26 08:00 PM
Conroy Kevin T	President and CEO	Feb 25 '25	Option Exercise	0.00	13,180	0	1,121,378	Feb 26 08:00 PM
Conroy Kevin T	President and CEO	Feb 19 '25	Option Exercise	0.00	10,374	0	1,084,565	Feb 21 04:30 PM
COWARD D SCOTT	Director	Feb 19 '25	Option Exercise	0.00	2,248	0	52,831	Feb 21 04:30 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 19 '25	Option Exercise	0.00	2,248	0	16,688	Feb 21 04:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 19 '25	Option Exercise	0.00	1,729	0	14,487	Feb 21 04:30 PM
Condella Sarah	EVP, Human Resources	Feb 19 '25	Option Exercise	0.00	2,248	0	74,859	Feb 21 04:30 PM
Herriott James	SVP, General Counsel & Sec	Feb 19 '25	Option Exercise	0.00	865	0	10,731	Feb 21 04:30 PM

ESPR

Esperion Therapeutics Inc

EXAS

Exact Sciences Corp

Upgrade your FINVIZ experience